JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Rahul Khara, the Chief Legal Officer of Disc Medicine, Inc. (NASDAQ:IRON), a $1.83 billion market cap biotech company with strong financial health according to InvestingPro, recently sold shares of the company’s common stock, according to an SEC filing. On February 18, Khara sold 1,161 shares at a price of $54.58 each, amounting to a total transaction value of $63,367. This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units granted earlier. Following this transaction, Khara holds 37,583 shares in the company. The stock, currently trading at $54.35, has shown significant volatility, with analyst targets ranging from $73 to $118. InvestingPro subscribers have access to 10 additional key insights about IRON’s financial outlook and performance metrics.
In other recent news, Disc Medicine has been the subject of attention following updates from analysts and upcoming data presentations. Stifel has raised its price target for the company to $94, maintaining a Buy rating, after Disc Medicine received authorization to submit a new drug application for bitopertin. The analyst at Stifel estimates an 85% chance of approval for the drug, which is aimed at treating erythropoietic protoporphyria, with a potential commercial launch in 2026. Meanwhile, Jefferies has also maintained a Buy rating for Disc Medicine, setting a higher price target of $111. This outlook is based on anticipated positive data from an upcoming presentation at the American Society of Hematology, which is expected to demonstrate superior efficacy and safety for DISC-0974™ compared to competitors. The presentation will include six-month data from all dose cohorts, including the highest 100mg dosage, and aims to differentiate DISC-0974™ in the market. Disc Medicine plans to reveal details about its Phase 2 trial design during an investor event following the presentation. These developments suggest a strong focus on clinical progress and potential market impact.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.